1. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
   Esther A. Kleibeuker et al, 2015, Cancer Medicine CrossRef
2. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better
   Simona Mura et al, 2016, Biochimie CrossRef
3. Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
   Joanna M. Brell et al, 2012, Cancer Chemotherapy and Pharmacology CrossRef
4. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report
   Adeline Guais et al, 2012, Investigational New Drugs CrossRef
5. Inhibition of Melanoma Angiogenesis by Telomere Homolog Oligonucleotides
   Christina Coleman et al, 2010, Journal of Oncology CrossRef
6. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer
   Niranjan Awasthi et al, 2011, HPB CrossRef
7. Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
   Hop S. Tran Cao et al, 2010, Molecular Cancer Therapeutics CrossRef
8. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model
   Hidenobu Ishizaki et al, 2011, Cancer Immunology, Immunotherapy CrossRef
9. Tyrosine kinase receptor inhibitor‐targeted combined chemotherapy for metastatic bladder cancer
   Chia‐Lun Wu et al, 2012, The Kaohsiung Journal of Medical Sciences CrossRef
10. Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer
    Rui Kong et al, 2010, Cancer Letters CrossRef
11. Sunitinib-Induced Pseudoprogression After Whole-Brain Radiotherapy for Metastatic Renal Cell Carcinoma
    Paul J. Kelly et al, 2010, Journal of Clinical Oncology CrossRef
12. Multicompartimental Nanoparticles for Co-Encapsulation and Multimodal Drug Delivery to Tumor Cells and Neovasculature
    Lívia Palmerston Mendes et al, 2013, Pharmaceutical Research CrossRef
13. miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies
    Deepak Chitkara et al, 2015, Advanced Drug Delivery Reviews CrossRef
14. Synthesis and Cytotoxic Activity of Self‐Assembling Squalene Conjugates of 3‐[(Pyrrol‐2‐yl)methylidene]‐2,3‐dihydro‐1H‐indol‐2‐one Anticancer Agents
    Eric Buchy et al, 2015, European Journal of Organic Chemistry CrossRef
15. PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer
    Duk Ki Kim et al, 2022, Nature Communications CrossRef
16. Noninvasive Monitoring of Therapy-Induced Microvascular Changes in a Pancreatic Cancer Model Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with P846, a New Low-Diffusible Gadolinium-Based Contrast Agent
    Veerle F. Casneuf et al, 2011, Radiation Research CrossRef
17. Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights
    Louke J. Delrue et al, 2011, Magnetic Resonance Materials in Physics, Biology and Medicine CrossRef
18. Role of Stroma in Pancreatic Cancer
    Malin Sund, 2021, Textbook of Pancreatic Cancer CrossRef